Investment Highlights for StageZero Life Sciences, Ltd

Investment Highlights for
StageZero Life Sciences, Ltd (SZLS-TSX)

StageZero Life Sciences, Ltd (“StageZero” or “the Company”) is a revenue-generating innovator in the liquid biopsy space, focused on developing and commercializing proprietary blood-based diagnostic solutions to aid in the detection of cancer at the earliest possible stage, as well as other disease states.

The Company’s proprietary Sentinel Principle® technology platform is a liquid biopsy technology that uses a blood sample to detect cancer and other disease. The technology is based on the scientific observation that circulating blood reflects, in a detectable way, what is occurring throughout the body. Thus, by conducting a minimally invasive blood draw, the Company can analyze the blood sample to detect cancer and other diseases.

StageZero believes that its products can improve a patient’s prognosis. Early detection of cancer has been proven to improve survival rates and quality of life, and yet 40% of screenable cancers are diagnosed late.

The science behind the Sentinel Principle® led to the development of the Company’s flagship product, ColonSentry®, a blood-based test for assessing an individual’s risk of having colorectal cancer (CRC). Initially developed from a clinical study involving approximately 10,000 subjects, ColonSentry® was commercialized in 2014 and has been used successfully in over 100,000 patients throughout the U.S.

- ColonSentry® is a patient-friendly, blood-based test that can be easily incorporated into a patient’s routine annual exam, providing significant clinical advantages: (1) patients are two-times more likely to comply with a colonoscopy following an elevated ColonSentry® score; (2) it increases the effectiveness of colonoscopies, detecting 2.1 to 4.7 times more CRC lesions following a ColonSentry® test; and (3) it provides financial benefits reducing healthcare costs by more than 20% through early interventions.

StageZero also offers diagnostics tests to assess the probability of having four of the most prevalent cancers: CRC, lung (EarlyCDT®-Lung), prostate (Prostate Health Index [phi]), and breast cancer (BreastSentry™).

StageZero is utilizing its Sentinel Principle® technology for the development of its next generation test, Aristotle™, expected to launch in 2021. Aristotle™ is a multi-cancer panel for the simultaneous screening of 10 cancers (CRC, prostate, cervical, endometrial, breast, ovarian, liver, bladder, nasopharyngeal, and stomach cancer) from a single blood sample.
- The Company is also planning to expand the applications of Aristotle™ beyond oncology, to help in the diagnosis of disease in gastroenterology, neurology, cardiology, and autoimmune disorders.

The Company’s commercialization strategy aims to shorten the lengthy market-entry process of new diagnostic tests, targeting four market segments: (1) physician practices; (2) telemedicine–consumer directed; (3) large healthcare systems; and (4) large employers/high risk populations.
- On March 2019, StageZero launched its first nationwide telehealth initiative, making its phi test available for online purchase through its portal com. The Company has begun to process initial patient orders.

- The Company has experienced early success with a Midwest hospital system. It has initiated a contract with a large healthcare system to offer its array of cancer screening tools and has engaged with other healthcare groups.

- In the large employer/high risk market, StageZero began screening firefighter groups, and has been engaged with another large employer, with over 100,000 employees, for the use of its products.

The Company also operates a CAP-accredited and CLIA-certified laboratory based in Richmond, Virginia that conducts sample processing for the ColonSentry® test as well as for the licensed biomarker tests for lung, breast, and prostate cancers.
StageZero’s long term goals center around two key milestones: achieving profitability (2020) and launching the Aristotle™ test (2021). As of September 30, 2019, the Company had $411,445 in cash and cash equivalents.